These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24874647)

  • 1. Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.
    Van Horn KS; Zhu X; Pandharkar T; Yang S; Vesely B; Vanaerschot M; Dujardin JC; Rijal S; Kyle DE; Wang MZ; Werbovetz KA; Manetsch R
    J Med Chem; 2014 Jun; 57(12):5141-56. PubMed ID: 24874647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.
    Zhu X; Van Horn KS; Barber MM; Yang S; Wang MZ; Manetsch R; Werbovetz KA
    Bioorg Med Chem; 2015 Aug; 23(16):5182-9. PubMed ID: 25749014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents.
    Zhu X; Farahat AA; Mattamana M; Joice A; Pandharkar T; Holt E; Banerjee M; Gragg JL; Hu L; Kumar A; Yang S; Wang MZ; Boykin DW; Werbovetz KA
    Bioorg Med Chem Lett; 2016 May; 26(10):2551-2556. PubMed ID: 27048943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines.
    Van Horn KS; Burda WN; Fleeman R; Shaw LN; Manetsch R
    J Med Chem; 2014 Apr; 57(7):3075-93. PubMed ID: 24625106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of chalcones as potential antileishmanial agents.
    Gupta S; Shivahare R; Korthikunta V; Singh R; Gupta S; Tadigoppula N
    Eur J Med Chem; 2014 Jun; 81():359-66. PubMed ID: 24858541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antileishmanial activity of aldonamides and N-acyl-diamine derivatives.
    Coimbra ES; Almeida CG; Júnior WV; Dos Reis RC; De Almeida AC; Forezi LS; De Almeida MV; Le Hyaric M
    ScientificWorldJournal; 2008 Jul; 8():752-6. PubMed ID: 18677429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileishmanial effects of clofazimine and other antimycobacterial agents.
    Evans AT; Croft SL; Peters W; Neal RA
    Ann Trop Med Parasitol; 1989 Oct; 83(5):447-54. PubMed ID: 2619361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
    Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
    Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of and initial mechanistic studies on a novel antileishmanial agent identified through in silico pharmacophore development and database searching.
    Delfín DA; Bhattacharjee AK; Yakovich AJ; Werbovetz KA
    J Med Chem; 2006 Jul; 49(14):4196-207. PubMed ID: 16821779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of leishmanicidal and trypanocidal activities of aliphatic diamine derivatives.
    Yamanaka CN; Giordani RB; Rezende CO; Eger I; Kessler RL; Tonini ML; de Moraes MH; Araújo DP; Zuanazzi JA; de Almeida MV; Steindel M
    Chem Biol Drug Des; 2013 Dec; 82(6):697-704. PubMed ID: 23865595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel arylimidamides for treatment of visceral leishmaniasis.
    Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new antileishmanial leads from hits obtained by high-throughput screening.
    Zhu X; Pandharkar T; Werbovetz K
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1182-9. PubMed ID: 22143523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,3-Bis(aryloxy)propan-2-ols as potential antileishmanial agents.
    Lavorato SN; Duarte MC; Lage DP; Tavares CAP; Coelho EAF; Alves RJ
    Chem Biol Drug Des; 2017 Nov; 90(5):981-986. PubMed ID: 28590516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, cytotoxicity, and in vitro antileishmanial activity of mono-t-butyloxycarbonyl-protected diamines.
    Pinheiro AC; Rocha MN; Nogueira PM; Nogueira TC; Jasmim LF; de Souza MV; Soares RP
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):273-8. PubMed ID: 21907525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of lansine analogues as antileishmanial agents.
    Pieroni M; Girmay S; Sun D; Sahu R; Tekwani BL; Tan GT
    ChemMedChem; 2012 Nov; 7(11):1895-900. PubMed ID: 22987791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis.
    Ramos GS; Vallejos VMR; Ladeira MS; Reis PG; Souza DM; Machado YA; Ladeira LO; Pinheiro MBV; Melo MN; Fujiwara RT; Frézard F
    Biomed Pharmacother; 2021 Feb; 134():111120. PubMed ID: 33341671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, Plasmodium falciparum Inhibitory Activity, Cytotoxicity and Solubility of N2 ,N4 -Disubstituted Quinazoline-2,4-diamines.
    Pobsuk N; Suphakun P; Hannongbua S; Nantasenamat C; Choowongkomon K; Gleeson MP
    Med Chem; 2019; 15(6):693-704. PubMed ID: 30569870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel steroid derivatives: synthesis, antileishmanial activity, mechanism of action, and in silico physicochemical and pharmacokinetics studies.
    da Trindade Granato J; Dos Santos JA; Calixto SL; Prado da Silva N; da Silva Martins J; da Silva AD; Coimbra ES
    Biomed Pharmacother; 2018 Oct; 106():1082-1090. PubMed ID: 30119174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
    Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
    J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo antileishmanial action of Ir-(COD)-pentamidine tetraphenylborate on Leishmania donovani and Leishmania major mouse models.
    Loiseau PM; Mbongo N; Bories C; Boulard Y; Craciunescu DG
    Parasite; 2000 Jun; 7(2):103-8. PubMed ID: 10887656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.